[{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Chroma Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chroma Medicine \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Chroma Medicine \/ Google Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Chroma Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Interphex
Not Confirmed
Interphex
Not Confirmed

Details : The funding will be used to progress chroma’s single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

January 03, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Technology

Highest Development Status : Preclinical

Sponsor : Google Ventures

Deal Size : $135.0 million

Deal Type : Series B Financing

blank